Saturday 17 October 2026
Export STRO’s income statement to Excel — free account
Sutro Biopharma, Inc.
STRO Healthcare Biotechnology
Sutro Biopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $102.5 million, up 65.2% from fiscal 2024. In the quarter to June 2026, revenue fell 84.6%, EPS fell 66.4% and free cash flow grew 14.6%, each against the same quarter a year earlier.
10.94
0.52
−4.54%
Follow STRO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.70 | 0.96 | 3.27 | 12.04 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(1.93) | (3.72) | (7.71) | (14.37) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
(0.81) | (0.34) | 1.32 | 8.61 | |
EV/EBITDA |
0.47 | 0.23 | 0.00 | 0.00 | |
EV/Operating CF |
0.39 | 0.20 | (0.87) | (2.71) | |
EV/FCF |
0.38 | 0.20 | (0.86) | (2.70) | |
Quick Ratio |
2.39 | 1.94 | 3.04 | 3.22 | |
Current Ratio |
2.53 | 2.01 | 3.12 | 3.32 | |
Net Debt/EBITDA |
3.54 | 3.83 | 7.03 | 5.65 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.32 | 0.37 | 0.35 | 0.20 | |
Operating CF/Net income |
0.67 | 0.57 | 1.10 | 0.99 | |
Capex/Depreciation |
(0.22) | (0.17) | (0.01) | 0.00 | |
Research and Development Expense of Revenue |
411.15% | 314.60% | 251.69% | 322.14% | |
Selling, General and Administrative Expense of Revenue |
90.18% | 74.37% | 52.22% | 79.59% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
16.01% | 14.21% | 10.76% | 20.43% | |
Graham Net Nets |
(1.55) | (1.58) | (0.27) | (0.22) | |
Graham Number |
77.71 | 88.94 | 43.43 | 49.30 | |
Earnings Yield |
(300.00%) | (194.93%) | (65.81%) | (52.18%) | |
Free Cash Flow Yield |
(304.88%) | (181.98%) | (46.69%) | (26.47%) | |
Revenue per Share |
1.14 | 1.37 | 1.11 | 0.59 | |
Operating CF per Share |
(4.50) | (3.11) | (3.23) | (2.31) | |
Capex per Share |
(0.03) | (0.02) | 0.00 | 0.00 | |
Free Cash Flow per Share |
(4.53) | (3.13) | (3.23) | (2.31) | |
Cash per Share |
19.75 | 16.64 | 15.48 | 9.92 | |
Shareholders Equity per Share |
(10.28) | (15.59) | (5.11) | (6.23) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(10.28) | (15.59) | (5.11) | (6.23) | |
Free Cash Flow |
(38.44) | (26.62) | (42.27) | (38.29) | |
Working Capital |
110.22 | 75.79 | 150.16 | 122.75 | |
Capital Expenditures |
(0.25) | (0.18) | (0.01) | 0.00 | |
Net Current Asset Value |
(114.81) | (155.36) | (87.90) | (122.13) | |
EV/EBIT |
0.46 | 0.22 | 0.00 | 0.00 | |
Capex to Sales |
0.03 | 0.02 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
5.29 | 6.30 | 13.02 | 6.90 | |
Average Payables |
6.63 | 9.02 | 6.83 | 3.83 | |
Average Assets |
330.75 | 280.52 | 281.71 | 228.41 | |
Average Common Equity |
11.98 | (43.93) | (46.35) | (67.71) |
Columns are period end dates